AAM
KYMR icon

Advisors Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Advisors Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Sell
4,878
-63
-1% -$4.99K 0.01% 1011
2025
Q4 		$384K Sell
4,941
-2
-0% -$135 0.01% 1015
2025
Q3 		$280K Sell
4,943
-19
-0.4% -$857 ﹤0.01% 1076
2025
Q2 		$217K Buy
4,962
+3
+0.1% +$103 ﹤0.01% 1109
2025
Q1 		$136K Buy
4,959
+2,230
+82% +$81.3K ﹤0.01% 1151
2024
Q4 		$110K Buy
+2,729
New +$123K ﹤0.01% 1209
2024
Q1 		– Sell
-6,893
Closed -$175K – 1422
2023
Q4 		$175K Sell
6,893
-155
-2% -$2.77K ﹤0.01% 1129
2023
Q3 		$98K Sell
7,048
-78
-1% -$1.57K ﹤0.01% 1194
2023
Q2 		$164K Sell
7,126
-550
-7% -$15.8K ﹤0.01% 1149
2023
Q1 		$227K Buy
7,676
+5,349
+230% +$173K ﹤0.01% 1090
2022
Q4 		$58.1K Buy
+2,327
New +$62K ﹤0.01% 1325

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Advisors Asset Management's KYMR Position: Q1 2026 in Review

Advisors Asset Management reduced its Kymera Therapeutics (KYMR) stake by 1.3% in Q1 2026, selling an estimated $4.99K and leaving 4,878 shares worth $406K. The position accounts for 0.01% of the portfolio, ranked #1011.

Advisors Asset Management first reported a position in KYMR in Q4 2022 and has held it in 11 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Advisors Asset Management held 4,878 shares of Kymera Therapeutics worth $406K as of Q1 2026.
  • Advisors Asset Management sold 63 Kymera Therapeutics shares in Q1 2026, an estimated $4.99K.
  • Kymera Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1011 holding.
  • Advisors Asset Management first reported a position in Kymera Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.